Ozempic Gastroparesis Leads

Better Than Buying Ozempic Gastroparesis Leads

Legal Calls sells exclusive Ozempic gastroparesis leads and signed retainers to law firms. Claimants allege GLP-1 drugs such as Ozempic, Wegovy and Mounjaro caused gastroparesis, ileus or bowel obstruction. Leads come from our own Meta, TikTok and Google ads, are screened for a gastric emptying study, and are delivered by CRM, API, email or warm transfer.

Ozempic Gastroparesis Leads & Signed Retainers

Superior Performance, Superior Pricing

To get a Custom Quote Today

Ozempic Gastroparesis Leads: Key Facts & Litigation Status

Ozempic Gastroparesis Leads at a Glance

Case typePharmaceutical product liability (GLP-1 receptor agonists)
LitigationMDL No. 3094, E.D. Pa., Judge Karen S. Marston (created Feb 2, 2024)
Alleged injuriesGastroparesis, ileus, intestinal or gastric obstruction
Lead sourcesMeta, TikTok & Google ads — no affiliates
What you getExclusive leads or signed retainers
DeliveryCRM, API, email or warm transfer
IntakeIn-house team, under 1-minute speed-to-lead
ProofTrustedForm certificate, call recordings, ad account access
VolumeOn request
Last reviewedNovember 2026

Ozempic Gastroparesis Litigation Status

GLP-1 gastrointestinal injury claims are centralized in MDL No. 3094, In re: GLP-1 RAs Products Liability Litigation, in the Eastern District of Pennsylvania before Judge Karen S. Marston. The MDL was created on February 2, 2024. Defendants are Novo Nordisk and Eli Lilly.

On August 15, 2025, the court ruled that plaintiffs alleging gastroparesis must show the diagnosis rested on a properly performed gastric emptying study. Expert opinions that gastroparesis can be diagnosed without one were excluded. For intake, gastroparesis claims without that test are unlikely to be viable in the MDL.

Summary-judgment briefing was completed in August 2026. The court held a Rule 702 hearing on cross-cutting expert issues on September 14-18, 2026 and heard closing arguments in mid-October. As of November 2026, no ruling on those motions had been reported. More than 4,000 actions were pending in fall 2026, per JPML reports.

No bellwether trial date or MDL-wide settlement had been announced as of November 2026. GLP-1 vision-loss (NAION) claims are not part of this MDL; they are in a separate MDL 3163 before the same judge.

Sources: GLP-1 MDL Requires Objective Testing to Proceed (Dechert) · Trimming Down the GLP-1 MDL (Drug & Device Law Blog) · GLP-1 Lawsuits & Enforcement Tracker (The Rx Index) · MDL 3094 GLP-1 RA Litigation Update (MDL Update). Status as of November 2026.

What Sets Us Apart From Other Ozempic Gastroparesis Lead Vendors?

Years of Excellence
14 +
Ad Spend Managed
78 M+
Leads Delivered
390 k+

Real Customers, Real Satisfaction

Ozempic Gastroparesis Client Acquisition Example Criteria & Pricing

Criteria shown is generalized based on current standards in this mass tort. Tailored criteria sets are available to meet client specifications.

To get a Custom Quote Today

How It Works & Pricing

How Our Ozempic Gastroparesis Campaigns Work

  1. We run our own Meta, TikTok and Google ads aimed at GLP-1 users with serious stomach or bowel injuries.
  2. Pre-screen questions confirm the drug, the diagnosis and whether a gastric emptying study was done.
  3. Our in-house intake team calls within a minute to verify treatment, timing and available medical records.
  4. Qualified claimants are delivered to your firm by CRM, API, email or warm transfer, or as signed retainers.

Leads or Signed Retainers — Your Choice

Exclusive Ozempic Gastroparesis leads: pre-screened claimants delivered in real time to your CRM, by API, by email or as a warm transfer, for your own team to sign.

Signed Ozempic Gastroparesis retainers: our in-house intake team qualifies the claimant and collects the signed retainer and HIPAA authorization before the case is delivered.

Pricing: a percentage of ad spend, or a fixed price per signed retainer. Volume is available on request.

More about Our Ozempic Gastroparesis Client Acquisition Signed Retainers

Ozempic Gastroparesis Leads: Frequently Asked Questions

Is there an MDL for Ozempic gastroparesis?

Yes. MDL No. 3094 in the Eastern District of Pennsylvania, before Judge Karen S. Marston, covers GLP-1 gastrointestinal injury claims. More than 4,000 actions were pending in fall 2026, per JPML reports.

What injuries qualify?

Gastroparesis confirmed by a gastric emptying study, plus ileus and intestinal or gastric obstruction, especially where hospitalization or surgery followed. Ileus and obstruction claims are documented through medical records rather than a gastric emptying study.

Why does the gastric emptying study matter?

An August 15, 2025 MDL ruling held that gastroparesis claims must rest on a properly performed gastric emptying study. We screen for this test so you can prioritize viable files.

Are your Ozempic gastroparesis leads exclusive?

Yes. Each lead is sold to one firm only and comes from our own ads, not affiliates, with a TrustedForm certificate and call recording.

Do you sell signed Ozempic gastroparesis retainers?

Yes. Firms can buy exclusive leads or signed retainers, priced as a percentage of ad spend or a fixed price per signed retainer.

Is there a bellwether trial date or settlement?

Not as of November 2026. The Rule 702 expert motions were argued in fall 2026 and a ruling was pending, with no bellwether date or global settlement announced.

Related Mass Tort Leads

Ozempic NAION Leads · Ozempic Leads · Depo-Provera Leads · Mass Tort Intake · All mass tort case leads

Are You Price-Shopping for Ozempic Gastroparesis Leads?

Prices are always changing and tend to rise over time. We work with you to get the lowest client acquisition cost in the industry by tailoring our service to your needs.

Book a time with our VP, and he’ll walk you through pricing and strategy step by step.